Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 Patients

Next Previous
X
Search
Trial Profile

Phase I Study to Evaluate the Safety, Tolerability, and Pharmacodynamics (PD) of DWRX2003 (Niclosamide IM Depot) Injection Following Intramuscular Administration in COVID-19 Patients

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niclosamide (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Daewoong Pharmaceutical

    • Most Recent Events

    • 16 Sep 2021 Status changed from not yet recruiting to discontinued. (Enrolment was suspended since 09Dec2020 due to a lack of COVID-19 patients.)
    • 10 Sep 2020 New trial record
    • 07 Sep 2020 According to a Daewoong Pharmaceutical media release, the Food and Drug Administration (FDA) of the Philippines has approved for this study. The study will begin in Sep 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top